260 related articles for article (PubMed ID: 36647006)
1. Medium-term real-world data for erenumab in 177 treatment resistant or difficult to treat chronic migraine patients: persistence and patient reported outcome measures after 17-30 months.
Troy E; Shrukalla AA; Buture A; Conaty K; Macken E; Lonergan R; Melling J; Long N; Shaikh E; Birrane K; Tomkins EM; Goadsby PJ; Ruttledge MH
J Headache Pain; 2023 Jan; 24(1):5. PubMed ID: 36647006
[TBL] [Abstract][Full Text] [Related]
2. Two-year, real-world erenumab persistence and quality of life data in 82 pooled patients with abrupt onset, unremitting, treatment refractory headache and a migraine phenotype: New daily persistent headache or persistent post-traumatic headache in the majority of cases.
Buture A; Tomkins EM; Shukralla A; Troy E; Conaty K; Macken E; Lonergan R; Melling J; Long N; Birrane K; Shaikh E; Goadsby PJ; Ruttledge MH
Cephalalgia; 2023 Jun; 43(6):3331024231182126. PubMed ID: 37317535
[TBL] [Abstract][Full Text] [Related]
3. Erenumab in chronic migraine: Patient-reported outcomes in a randomized double-blind study.
Lipton RB; Tepper SJ; Reuter U; Silberstein S; Stewart WF; Nilsen J; Leonardi DK; Desai P; Cheng S; Mikol DD; Lenz R
Neurology; 2019 May; 92(19):e2250-e2260. PubMed ID: 30996060
[TBL] [Abstract][Full Text] [Related]
4. Multidimensional assessment of the effects of erenumab in chronic migraine patients with previous unsuccessful preventive treatments: a comprehensive real-world experience.
Russo A; Silvestro M; Scotto di Clemente F; Trojsi F; Bisecco A; Bonavita S; Tessitore A; Tedeschi G
J Headache Pain; 2020 Jun; 21(1):69. PubMed ID: 32517693
[TBL] [Abstract][Full Text] [Related]
5. Impact of a reimbursement policy change on treatment with erenumab in migraine - a real-world experience from Germany.
Hong JB; Lange KS; Fitzek M; Overeem LH; Triller P; Siebert A; Reuter U; Raffaelli B
J Headache Pain; 2023 Oct; 24(1):144. PubMed ID: 37899428
[TBL] [Abstract][Full Text] [Related]
6. Long-term (48 weeks) effectiveness, safety, and tolerability of erenumab in the prevention of high-frequency episodic and chronic migraine in a real world: Results of the EARLY 2 study.
Barbanti P; Aurilia C; Cevoli S; Egeo G; Fofi L; Messina R; Salerno A; Torelli P; Albanese M; Carnevale A; Bono F; D'Amico D; Filippi M; Altamura C; Vernieri F;
Headache; 2021 Oct; 61(9):1351-1363. PubMed ID: 34309862
[TBL] [Abstract][Full Text] [Related]
7. Does MIDAS reduction at 3 months predict the outcome of erenumab treatment? A real-world, open-label trial.
De Icco R; Vaghi G; Allena M; Ghiotto N; Guaschino E; Martinelli D; Ahmad L; Corrado M; Bighiani F; Tanganelli F; Bottiroli S; Cammarota F; Sances G; Tassorelli C
J Headache Pain; 2022 Sep; 23(1):123. PubMed ID: 36115947
[TBL] [Abstract][Full Text] [Related]
8. Erenumab (AMG 334) in episodic migraine: Interim analysis of an ongoing open-label study.
Ashina M; Dodick D; Goadsby PJ; Reuter U; Silberstein S; Zhang F; Gage JR; Cheng S; Mikol DD; Lenz RA
Neurology; 2017 Sep; 89(12):1237-1243. PubMed ID: 28835404
[TBL] [Abstract][Full Text] [Related]
9. Two-year effectiveness of erenumab in resistant chronic migraine: a prospective real-world analysis.
Andreou AP; Fuccaro M; Hill B; Murphy M; Caponnetto V; Kilner R; Lambru G
J Headache Pain; 2022 Nov; 23(1):139. PubMed ID: 36333710
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of erenumab and factors predicting response after 3 months in treatment resistant chronic migraine: a clinical service evaluation.
Lowe M; Murray L; Tyagi A; Gorrie G; Miller S; Dani K;
J Headache Pain; 2022 Jul; 23(1):86. PubMed ID: 35869443
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and tolerability of erenumab in patients with episodic migraine in whom two-to-four previous preventive treatments were unsuccessful: a randomised, double-blind, placebo-controlled, phase 3b study.
Reuter U; Goadsby PJ; Lanteri-Minet M; Wen S; Hours-Zesiger P; Ferrari MD; Klatt J
Lancet; 2018 Nov; 392(10161):2280-2287. PubMed ID: 30360965
[TBL] [Abstract][Full Text] [Related]
12. Migraine-related disability, impact, and health-related quality of life among patients with episodic migraine receiving preventive treatment with erenumab.
Buse DC; Lipton RB; Hallström Y; Reuter U; Tepper SJ; Zhang F; Sapra S; Picard H; Mikol DD; Lenz RA
Cephalalgia; 2018 Sep; 38(10):1622-1631. PubMed ID: 30086681
[TBL] [Abstract][Full Text] [Related]
13. Erenumab in the prevention of high-frequency episodic and chronic migraine: Erenumab in Real Life in Italy (EARLY), the first Italian multicenter, prospective real-life study.
Barbanti P; Aurilia C; Egeo G; Fofi L; Cevoli S; Colombo B; Filippi M; Frediani F; Bono F; Grazzi L; Salerno A; Mercuri B; Carnevale A; Altamura C; Vernieri F
Headache; 2021 Feb; 61(2):363-372. PubMed ID: 33337544
[TBL] [Abstract][Full Text] [Related]
14. Erenumab in highly therapy-refractory migraine patients: First German real-world evidence.
Scheffler A; Messel O; Wurthmann S; Nsaka M; Kleinschnitz C; Glas M; Naegel S; Holle D
J Headache Pain; 2020 Jul; 21(1):84. PubMed ID: 32620151
[TBL] [Abstract][Full Text] [Related]
15. A real-world, observational study of erenumab for migraine prevention in Canadian patients.
Becker WJ; Spacey S; Leroux E; Giammarco R; Gladstone J; Christie S; Akaberi A; Power GS; Minhas JK; Mancini J; Rochdi D; Filiz A; Bastien N
Headache; 2022 Apr; 62(4):522-529. PubMed ID: 35403223
[TBL] [Abstract][Full Text] [Related]
16. A prospective real-world analysis of erenumab in refractory chronic migraine.
Lambru G; Hill B; Murphy M; Tylova I; Andreou AP
J Headache Pain; 2020 Jun; 21(1):61. PubMed ID: 32487102
[TBL] [Abstract][Full Text] [Related]
17. Erenumab efficacy in migraine headache prophylaxis: A systematic review.
Bagherzadeh-Fard M; Amin Yazdanifar M; Sadeghalvad M; Rezaei N
Int Immunopharmacol; 2023 Apr; 117():109366. PubMed ID: 37012858
[TBL] [Abstract][Full Text] [Related]
18. One-year prospective real-world assessment of effectiveness and safety of erenumab in migraine prevention: results of the French FHU INOVPAIN registry study.
Lanteri-Minet M; Fabre R; Martin C; Pradat K; Alchaar A; Bozzolo E; Duchene ML; Van Obberghen EK; Donnet A; Fontaine D
J Headache Pain; 2023 Nov; 24(1):152. PubMed ID: 37940860
[TBL] [Abstract][Full Text] [Related]
19. Pooled retrospective analysis of 70 mg erenumab in episodic and chronic migraine: a two tertiary headache centers experience during clinical practice.
Storch P; Burow P; Möller B; Kraya T; Heintz S; Politz N; Naegel S
Acta Neurol Belg; 2022 Aug; 122(4):931-937. PubMed ID: 34406609
[TBL] [Abstract][Full Text] [Related]
20. Real-World Patient Experience With Erenumab for the Preventive Treatment of Migraine.
Robblee J; Devick KL; Mendez N; Potter J; Slonaker J; Starling AJ
Headache; 2020 Oct; 60(9):2014-2025. PubMed ID: 32920850
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
